Work

WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.7005

Authors: Philippe Armand, Seung Tae Lee, Wojciech Jurczak, Don A. Stevens, Sylvain Choquet, Hervé Ghesquieres, Lalita Norasetthada, Antonio Pinto, Guray Saydam, Heng Zhou, Nishitha Reddy, Rushdia Zareen Yusuf, Muhit Ozcan

Institutions: Dana-Farber Cancer Institute, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Norton Healthcare, Pitié-Salpêtrière Hospital, Hôpital Lyon Sud, Maharaj Nakorn Chiang Mai Hospital, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Ege University, Ege Üniversitesi Tıp Fakültesi Hastanesi, Merck & Co., Inc., Rahway, NJ, USA (United States), Ankara University

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410821004

Cites:

Cited by: 3

Related to: 10